Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 16, 2016 - Issue 3
Submit an article Journal homepage
20,270
Views
30
CrossRef citations to date
0
Altmetric
Editorial

Advantages and disadvantages of discrete-event simulation for health economic analyses

J. Jaime CaroMcGill University, Montreal, Canada;Evidera, Boston, MA, USACorrespondence[email protected] [email protected]
&
Jörgen MöllerDivision of Health Economics, Lund University, Lund, Sweden;Evidera, London, UK
Pages 327-329 | Received 02 Feb 2016, Accepted 10 Mar 2016, Published online: 25 Mar 2016

References

  • Caro JJ. Disease-simulation models and health care decisions. Can Med Assoc J. 2000;162:1001–1002.
  • Caro JJ, Briggs AH, Siebert U, et al. Modeling good research practices—overview a report of the ISPOR-SMDM modeling good research practices task force–1. Med Decis Making. 2012;32:667–677.
  • Caro JJ, Möller J, Karnon J, et al. Discrete event simulation for health technology assessment. Boca Raton (FL): CRC Press, Taylor & Francis Group; 2015. 354 p.
  • Caro JJ. Pharmacoeconomic analyses using discrete event simulation. Pharmacoeconomics. 2005;23:323–332.
  • Karnon J, Stahl J, Brennan A, et al. Modeling using discrete event simulation a report of the ISPOR-SMDM modeling good research practices task force–4. Med Decis Making. 2012;32:701–711.
  • Caro JJ, Ishak KJ, Migliaccio-Walle K. Estimating survival for cost‐effectiveness analyses: a case study in atherothrombosis. Value Health. 2004;7:627–635.
  • Xenakis JG, Kinter ET, Ishak KJ, et al. A discrete-event simulation of smoking-cessation strategies based on varenicline pivotal trial data. Pharmacoeconomics. 2011;29:497–510.
  • Simpson KN, Pei PP, Möller J, et al. Lopinavir/ritonavir versus darunavir plus ritonavir for HIV infection: a cost-effectiveness analysis for the United States. Pharmacoeconomics. 2013;31:427–444.
  • Siebert U, Alagoz O, Bayoumi AM, et al., ISPOR-SMDM Modeling Good Research Practices Task Force. State-transition modeling: a report of the ISPOR-SMDM modeling good research practices task force-3. Value Health. 2012;15:812–820.
  • Caro JJ, Möller J. Decision-analytic models: current methodological challenges. Pharmacoeconomics. 2014;32:943–950.
  • Clarke PM, Gray AM, Briggs A, et al., UK Prospective Diabetes Study (UKPDS) Group. A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia. 2004;47:1747–1759.
  • Roberts M, Russell LB, Paltiel AD, et al. Conceptualizing a model a report of the ISPOR-SMDM modeling good research practices task force–2. Med Decis Making. 2012;32:678–689.
  • Caro JJ, Ishak KJ. No head-to-head trial? Simulate the missing arms. Pharmacoeconomics. 2010;28:957–967.
  • Jacobson SH, Hall SN, Swisher JR. Discrete-event simulation of health care systems. In: Hall RW, editor. Patient flow: reducing delay in healthcare delivery. Los Angeles (CA): Springer; 2006. p. 211–252.
  • Pei P, Kongnakorn T, Hernández L, et al. PCV93 discrete event simulation of cardiac hospitals performing percutaneous coronary interventions. Value Health. 2010;13:A167.
  • Eddy DM, Hollingworth W, Caro JJ, et al. Model transparency and validation a report of the ISPOR-SMDM Modeling Good Research Practices Task Force–7. Med Decis Making. 2012;32:733–743.
  • Knottnerus JA. Research data as a global public good. J Clin Epidemiol. 2016;70:270–271.
  • Caro JJ. Psst, have I got a model for you… Med Decis Making. 2015;35:139–141.
  • Caro JJ, Getsios D, Möller J. Regarding probabilistic analysis and computationally expensive models: necessary and required? Value Health. 2007;10:317–318.
  • Caro JJ, Möller J, Getsios D, et al. Invasive meningococcal disease epidemiology and control measures: a framework for evaluation. BMC Public Health. 2007;7:1.
  • Deniz B, Morgan G, Schey S, et al. Economic evaluation of lenalidomide combined with dexamethasone for the treatment of multiple myeloma in the UK. Blood. 2008;112:836–837.
  • Caro JJ. Discretely-integrated condition event (DICE) simulation for pharmacoeconomics. Pharmacoeconomics. Forthcoming 2016. doi:10.1007/s40273-016-0394-z.
  • Caro JJ, Möller J, Getsios D. Discrete event simulation: the preferred technique for health economic evaluations? Value Health. 2010;13:1056–1060.
  • Caro JJ, Eddy DM, Kan H, et al. Questionnaire to assess relevance and credibility of modeling studies for informing health care decision making: an ISPOR-AMCP-NPC Good Practice Task Force report. Value Health. 2014;17:174–182.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.